Dr. Gregory Scott Robinson Net Worth

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Dr Robinson AKUS stock SEC Form 4 insiders trading

Dr has made over 3 trades of the Akouos stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 410 units of AKUS stock worth $10,377 on 1 April 2019.

The largest trade he's ever made was selling 14,764 units of Akouos stock on 2 January 2019 worth over $164,619. On average, Dr trades about 2,228 units every 13 days since 2019. As of 1 April 2019 he still owns at least 103,182 units of Akouos stock.

You can see the complete history of Dr Robinson stock trades at the bottom of the page.

Dr. Gregory Scott Robinson biography

Dr. Gregory Scott Robinson is the Chief Scientific Officer at Akouos.

How old is Dr Robinson?

Dr Robinson is 62, he's been the Chief Scientific Officer of Akouos since . There are 1 older and 4 younger executives at Akouos. The oldest executive at Akouos, Inc. is Dr. Michael John McKenna M.D., 64, who is the Co-Founder, Chief Medical Officer & Member of Scientific Advisory Board.

What's Dr Robinson's mailing address?

Gregory's mailing address filed with the SEC is C/O AKOUOS, INC., 645 SUMMER STREET SUITE 200, BOSTON, MA, 02210.

Insiders trading at Akouos

Over the last 4 years, insiders at Akouos have traded over $16,920,000 worth of Akouos stock and bought 39,532,191 units worth $537,080,241 . The most active insiders traders include Forest Baskett, Scott D Sandell, eAnthony A. Jr. Florence. On average, Akouos executives and independent directors trade stock every 40 days with the average trade being worth of $24,448,882. The most recent stock trade was executed by Acquisition Corp Eli Lilly ... on 30 November 2022, trading 29,992,668 units of AKUS stock currently worth $374,908,350.

What does Akouos do?

Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.

Akouos executives and stock owners

Akouos executives and other stock owners filed with the SEC include:

• Dr. Emmanuel Simons M.B.A., Ph.D.,
  Co- Founder, Pres, CEO & Director
• Jennifer Anne Wellman M.S.,
  Chief Operating Officer
• Jennifer Anne Wellman,
  Chief Operating Officer
• Dr. Aaron Tward M.D., Ph.D.,
  Chief Scientific Officer
• Stacy Price,
  Chief Technical Officer
• Dr. Karoline K. Shair,
  Sr. VP, Gen. Counsel, Chief Legal Officer & Corp. Sec.
• Dr. Alan K. Smith,
  Chief Technology Officer
• Sachiyo Minegishi,
  CFO, Treasurer, Assistant Sec. & Principal Accounting Officer
• Richard Smith M.D.,
  Founder & Member of Scientific Advisory Board
• William F. Sewell Ph.D.,
  Founder & Member of Scientific Advisory Board
• Dr. Luk H. Vandenberghe M.D., Ph.D.,
  Founder & Member of Scientific Advisory Board
• Dr. Gregory Scott Robinson,
  Chief Scientific Officer
• Dr. Michael John McKenna M.D.,
  Co-Founder, Chief Medical Officer & Member of Scientific Advisory Board
• Venture Partners X, L.P.Sof...,
  
• Jennifer Anne Wellman,
  CHIEF OPERATING OFFICER
• Asset Management, Lp Chen B...,
  
• Edward T Mathers,
  Director
• Kush Parmar,
  Director
• Innovation Fund Ii, L.P. Pa...,
  10% owner
• Bioventures Ltd Novartis Ag...,
  
• Innovation Fund, Llc Partners,
  10% owner
• Heather Preston,
  Director
• Capital Management, L.P.Ra ...,
  
• Capital, Llc Eco R1,
  10% owner
• Saira Ramasastry,
  Director
• Bio Venture Partners Fund I...,
  
• Forest Baskett,
  10% owner
• Carmen Chang,
  10% owner
• Anthony A. Jr. Florence,
  10% owner
• Mohamad Makhzoumi,
  10% owner
• Joshua Makower,
  10% owner
• Scott D Sandell,
  10% owner
• Paul Edward Walker,
  10% owner
• Enterprise Associates 16, L...,
  
• Ali Behbahani,
  10% owner
• Peter W. Sonsini,
  10% owner
• Advisers Llc Marshfield,
  10% owner
• Michael John Mc Kenna,
  Chief Medical Officer
• Sachiyo Minegishi,
  Chief Financial Officer
• Gregory Scott Robinson,
  Chief Scientific Officer
• Emmanuel Simons,
  Chief Executive Officer
• Christopher M Smith,
  Director
• Vicki L Sato,
  Director
• Arthur Tzianabos,
  Director
• Acquisition Corp Eli Lilly ...,